DiNardo, C. D., Roboz, G. J., Stein, E. M., de Botton, S., Mims, A. S., Prince, G. T., … Stone, R. M. (2019). Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study. In Clinical Lymphoma Myeloma and Leukemia (Vol. 19, pp. S220–S220). Elsevier BV. https://doi.org/10.1016/j.clml.2019.07.094

DiNardo, Courtney D., Gail J. Roboz, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, et al. “Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study.” In Clinical Lymphoma Myeloma and Leukemia, 19:S220–S220. Elsevier BV, 2019. https://doi.org/10.1016/j.clml.2019.07.094.

DiNardo CD, Roboz GJ, Stein EM, de Botton S, Mims AS, Prince GT, et al. Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2019. p. S220–S220.

DiNardo, Courtney D., et al. “Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study.” Clinical Lymphoma Myeloma and Leukemia, vol. 19, Elsevier BV, 2019, pp. S220–S220. Crossref, doi:10.1016/j.clml.2019.07.094.

DiNardo CD, Roboz GJ, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM. Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2019. p. S220–S220.